NCT04009096View on ClinicalTrials.gov

VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions
Malaria, Vivax
Interventions
BIOLOGICAL

ChAd63 PvDBP and MVA PvDBP

one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology & Tropical Medicine, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT04009096 - VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines | Biotech Hunter | Biotech Hunter